Clarithromycin

EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS

Clarithromycin

---

CLASS

Macrolides

---

TARGET PROTEIN

23S rRNA on the 50s ribosomal subunit

---

MECHANISM OF ACTION

Bactericidal or bacteriostatic activity (It reversibly binds to the 23S rRNA on the 50s ribosomal subunit and subsequently prevents polypeptide synthesis)

---

DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)

Approved

---

MODE OF ADMINISTRATION

Oral

---

LINK TO PUBMED

https://pubmed.ncbi.nlm.nih.gov/32091697/ 

https://pubmed.ncbi.nlm.nih.gov/9687409/

https://pubmed.ncbi.nlm.nih.gov/30136733/

---

SIMILAR TARGETS IN OTHER SPECIES

50S ribosomal protein L10 ~ Shigella flexneri

---

DRUG BANK ID

DB01211

---

EXTERNAL LINKS

Human Metabolome Database HMDB0015342

KEGG Drug D00276

KEGG Compound C06912

PubChem Compound 84029

PubChem Substance 46506489

ChemSpider 10342604

BindingDB 50404044

RxNav 21212

ChEBI 3732

ChEMBL CHEMBL1741

ZINC ZINC000085534098

Drugs.com Drugs.com Drug Page https://www.drugs.com/clarithromycin.html

Wikipedia Clarithromycin

---

REFERENCE

Portaels, F., Traore, H., De Ridder, K., & Meyers, W. M. (1998). In vitro susceptibility of Mycobacterium ulcerans to Clarithromycin. Antimicrobial Agents and Chemotherapy, 42(8), 2070–2073. https://doi.org/10.1128/aac.42.8.2070 , 



Pluschke, G., & Röltgen, K. (2019). Buruli ulcer: Mycobacterium ulcerans disease. In Buruli Ulcer: Mycobacterium ulcerans Disease. https://doi.org/10.1007/978-3-030-11114-4



Yotsu, R. R., Richardson, M., & Ishii, N. (2018). Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). Cochrane Database of Systematic Reviews, 2018(8). https://doi.org/10.1002/14651858.CD012118.pub2



Organization, W. H. (2022). WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8 - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01659437

---